and Human Services (HHS)
EXPIRED
Department of Health and Human Services
Participating Organizations
Centers for Disease Control and Prevention (CDC), at (http://www.cdc.gov/)
Components of Participating Organizations
National Center for Injury
Prevention and Control (NCIPC) at (http://www.cdc.gov/ncipc/)
Title: Grants for Injury Control Research Centers
The CDC policies,
guidelines, terms, and conditions stated in this announcement may differ from
those used by the NIH.
Authority: This program is authorized under
section 301 (a) [42 U.S.C. 241(a)] of the Public Health Service Act, and Section
391 (a) [42 U.S.C. 280 b (a)] of the Public Service Health Act, as amended.
Announcement Type: New
Program Announcement (PA) Number: RFA-CE-07-001
Catalog of Federal Domestic Assistance Number:
93.136, Injury Prevention and Control Research
and State and Community Based Programs
Key Dates
Release Date: February 17, 2006
Letters of
Intent Receipt Date: 08/02/2006
Application
Receipt Dates: 09/01/2006
Peer
Review Date: 03/10/2007
Council
Review Date: 04/12/2007
Earliest
Anticipated Start Date: 09/01/2007
Additional
Information to Be Available Date: 03/30/2006
Technical assistance will be available
for potential applicants during one conference call. The call for eligible
applicants will be held on 03/30/2006 from 1:30 p.m. to 2:30 p.m. (Eastern
Time). The conference can be accessed by calling 1-800-475-8401 and entering pass
code ATIJANI. The leader is Ademola Tijani.
Expiration
Date: September 2, 2009
Due Dates for E.O. 12372
Executive Order
12372 does not apply to this program.
Additional
Overview Content
Executive Summary
Table of Contents
Part I Overview Information
Part
II Full Text of Announcement
Section
I. Funding Opportunity Description
1.
Research Objectives
Section
II. Award Information
1.
Mechanism(s) of Support
2.
Funds Available
Section
III. Eligibility Information
1.
Eligible Applicants
A. Eligible Institutions
B. Eligible Individuals
2.Cost
Sharing or Matching
3.
Other - Special Eligibility Criteria
Section
IV. Application and Submission Information
1.
Address to Request Application Information
2.
Content and Form of Application Submission
3.
Submission Dates and Times
A. Receipt and Review and Anticipated Start Dates
1. Letter of Intent
B. Sending an Application
C. Application Processing
4.
Intergovernmental Review
5.
Funding Restrictions
6.
Other Submission Requirements
Section
V. Application Review Information
1.
Criteria
2.
Review and Selection Process
A. Additional Review Criteria
B. Additional Review Considerations
C. Sharing Research Data
D. Sharing Research Resources
3.
Anticipated Announcement and Award Dates
Section
VI. Award Administration Information
1.
Award Notices
2.
Administrative and National Policy Requirements
A. Cooperative Agreement Terms and Conditions of Award
1. Principal Investigator Rights and
Responsibilities
2. CDC Responsibilities
3. Collaborative Responsibilities
3. Reporting
Section
VII. Agency Contact(s)
1.
Scientific/Research Contact(s)
2.
Peer Review Contact(s)
3.
Financial/ Grants Management Contact(s)
4. General Questions Contact(s)
Section VIII. Other Information - Required Federal
Citations
Part II - Full Text of Announcement
1. Research Objectives
The CDC and NCIPC are committed to achieving the health promotion and disease prevention objectives of "Healthy People 2010" and to measuring program performance as stipulated by the Government Performance and Review Act (GPRA). This PA addresses Healthy People 2010 priority area of injury and violence prevention and is in alignment with NCIPC’s performance goal to conduct a targeted program of research to reduce injury-related death and disability. For more information, see www.health.gov/healthypeople and www.whitehouse.gov/omb/mgmt-gpra/.
The purposes of the NCIPC Injury Control Research Centers (ICRC) program are to:
For the research component of this announcement, NCIPC is soliciting investigator-initiated research that will help expand and advance our understanding of fatal and nonfatal injuries and related disabilities, their causes, and prevention strategies. Relevant research objectives include the following:
1. Dissemination Research:
Conduct studies to build knowledge on methods, structures,
and processes to implement existing evidence-based interventions, programs and
policies to prevent injuries and related disabilities. This research is
intended to bridge the gap between prevention research and everyday practice by
building a knowledge base about how evidence-based prevention information and
strategies are disseminated, translated and integrated for use by communities
and policy makers. Evidence-based interventions, programs, and policies are
defined as those for which there is evidence of effectiveness in reducing injuries
and disabilities based on systematic reviews of the field or two or more well
designed studies.
2. Intervention Evaluation Research:
Evaluate the efficacy, effectiveness, and cost
effectiveness of primary prevention or control interventions, programs, and
policies to prevent injuries and related disabilities.
Rigorous evaluations are needed to determine the effectiveness of interventions, programs, and policies addressing the prevention or control of injuries. Experimental designs are strongly encouraged. However, NCIPC will consider other evaluation designs, if justified, as required by the needs and constraints in a particular setting.
For effective interventions, it is possible to do cost-effectiveness studies. To be comparable to other cost effectiveness studies, they should follow the guidelines in the following references:
Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
Haddix AC, Teutsch SM, Corso, PS. Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation. Second Edition. New York: Oxford University Press, 2003.
For randomized trials, applicants are encouraged to clearly state how study subjects, whether individuals or groups, were selected, randomized, and followed through the trial. One relevant useful guidance document is Moher D, Schulz KF, Altman D. The CONSORT Statement, JAMA 2001;285:1987-2001.
3. Foundational Research:
Foundational research covers the basic studies and public health surveillance
approaches that define and quantify the extent of an injury problem. These
activities establish the causes of injuries, create causal models for injury
prevention, and provide a foundation for developing theory-based interventions.
4. Developmental Research:
Developmental
research supports the design and preliminary testing of potential strategies to
prevent and control injuries. Included are risk-factor research and pilot and
feasibility studies that measure how interventions affect key variables in the
causal chain.
See Section VIII, Other Information
- Required Federal Citations, for policies related to this announcement.
Section II. Award
Information
1. Mechanism(s) of Support
This funding opportunity will
use the R49 grant award mechanism.
As an applicant, you will be solely responsible for planning, directing, and
executing the proposed project.
This funding opportunity uses the just-in-time budget concepts. It also uses
the non-modular budget format described in the PHS 398 application instructions
(see http://grants.nih.gov/grants/funding/phs398/phs398.html).
A detailed categorical budget for the "Initial Budget Period" and the
"Entire Proposed Period of Support" is to be submitted with the application.
2. Funds Available
The participating CIO, NCIPC, intends to commit approximately $5,433,000 (both direct and indirect costs) in FY 2007 to fund six awards. The average award amount will be $905,500. This includes both direct and indirect costs and is for the first 12- month budget period. An applicant may request a project period of up to five years. An applicant may request up to $1,055,500 (both direct and indirect costs) ($150,000 above the expected award amount to allow for the inclusion of the description of an additional large project as described in Section IV. Application and Submission Information, 2. Content and Form of Application Submission 4.b. (2), but each award will be no more than $905,500 (both direct and indirect costs). The approximate total project period funded amount is $4,527,500 (including both direct and indirect costs), with a maximum of $905,500 per year. The anticipated start date for new awards is September, 2007.
All estimated funding amounts are subject to availability of funds.
Consideration will also be given to current NCIPC ICRC grantees who submit a competitive supplement application requesting one year of funding to enhance or expand existing projects, or to conduct one-year pilot studies. These awards will not exceed $150,000 (both direct and indirect costs). Supplemental awards will be made for the budget period to coincide with the actual budget period of the grant and are based on the availability of funds.
If you request a funding amount greater than the ceiling of the award range, your application will be considered non-responsive, and will not be entered into the review process. You will be notified that your application did not meet the submission requirements.
Although the financial plans of NCIPC provide support for this program, awards pursuant to this funding opportunity are contingent upon the availability of funds, evidence of satisfactory progress by the recipient (as documented in required reports), and the determination that continued funding is in the best interest of the Federal Government.
Facilities and administrative costs requested by consortium participants are not included in the direct cost limitation, see NOT-OD-05-004.
Use of Funds:
Center funding is to be designated for two types of activities. One type of activity is considered core and includes administration, management, general support services (e.g., statistical, library, media relations, and advocacy) as well as activities associated with research development, technical assistance, and education (e.g., seed projects, training activities, and collaborative and technical assistance activities with other groups). Funds may be allocated for trainee stipends, tuition remission, and trainee travel in accordance with the current rates for the United States Public Health Service agencies. Indirect costs for these trainee-related activities are limited to eight percent.
Defined research projects constitute the second type of activity, and ICRCs are encouraged to work toward addressing the breadth of the field. Core activities and defined research projects may each constitute between 25 percent and 75 percent of the operating budget, and should be balanced in such a way that the ICRC demonstrates productivity in research as well as teaching and service. Applicants with less demonstrated expertise in research are encouraged to devote a larger percentage of funds to defined research projects in order to establish their capability as research centers of excellence.
Grant funds will not be made available to support the provision of direct care. Studies may be supported which evaluate methods of acute care and rehabilitation for potential reductions in injury effects and costs. Studies may be supported which identify the effect on injury outcomes and cost of systems for pre-hospital, hospital, and rehabilitative care and independent living.
Eligible applicants may enter into contracts, including consortia agreements (as set forth in the PHS Grants Policy Statement, dated April 1, 1994), as necessary to meet the requirements of the program and strengthen the overall application.
Funding Preferences:
At the discretion of the Director, NCIPC, additional
consideration may be given to re-competing ICRCs. These centers represent a
long-term investment for NCIPC and an established resource for injury
control-related issues for their States and regions.
Section III. Eligibility Information
1. Eligible Applicants
1.A. Eligible Institutions
You may submit an application if your organization has any of the following characteristics:
A Bona Fide Agent is an agency/organization identified by the state as eligible to submit an application under the state eligibility in lieu of a state application. If you are applying as a bona fide agent of a state or local government, you must provide a letter from the state or local government as documentation of your status. Place this documentation behind the first page of your application form.
This announcement will provide funding for applicants in regions that do not have funded Injury Control Research Centers (ICRCs) and for applicants in regions that have funded Centers that must re-compete for funding.
Eligible applicants are limited to organizations in Department of Health and Human Services (DHHS) Region I (Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont), Region II (New Jersey, New York, Puerto Rico, and Virgin Islands), Region III (Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, and West Virginia), Region V (Illinois, Indiana, Michigan, Minnesota, Ohio, and Wisconsin), Region VI (Arkansas, Louisiana, New Mexico, Oklahoma, and Texas), Region VII (Iowa, Kansas, Missouri, and Nebraska), Region VIII (Colorado, Montana, North Dakota, South Dakota, Utah, and Wyoming), and Region IX (Arizona, California, Hawaii, Nevada, American Samoa, Guam, Mariana Islands, Marshall Islands, Micronesia, and Palau).
Note: ICRC grant awards are made to the applicant institution/organization, not the Principal Investigator.
1.B. Eligible Individuals
Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for CDC programs. Collaborations with foreign institutions are allowed if they provide injury prevention and control information relevant to the injury prevention and control problems in the United States.
To be an eligible applicant under this PA, the principal investigator must have conducted injury prevention research, published the findings in a peer-reviewed journal, and have specific authority and responsibility to carry out the proposed project. Applications from principal investigators who do not meet these requirements will be considered non-responsive and will not be reviewed.
2. Cost Sharing or Matching
Cost sharing, matching, or cost participation are not required.
The most current Grants Policy Statement can be found at: http://grants.nih.gov/grants/policy/gps/
3. Other-Special Eligibility Criteria
Applicants must be responsible for the following
activities:
Note: Title 2 of the United States Code Section 1611 states that an organization described in Section 501(c)(4) of the Internal Revenue Code that engages in lobbying activities is not eligible to receive Federal funds constituting an award, grant, or loan.
Section IV. Application and Submission Information
1. Address to Request Application Information
The PHS 398 application instructions are available at http://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive format. Applicants must use the currently approved version of the PHS 398. For further assistance contact GrantsInfo, Telephone (301) 710-0267, Email: [email protected].
Telecommunications for the hearing impaired: TTY 770-488-2783.
If you do not have access to the Internet, or if you have difficulty accessing the forms on-line, you may contact the CDC Procurement and Grants Office Technical Information Management Section (PGO-TIM) staff at: 770-488-2700. Application forms can be mailed to you.
2.
Content and Form of Application Submission
Applications
must be prepared using the most current PHS 398 research grant application
instructions and forms. Applications must have a Dun & Bradstreet (D&B)
Data Universal Numbering System number as the universal identifier when
applying for Federal grants or cooperative agreements. The D&B number can be obtained
by calling (866) 705-5711 or through the web site at http://www.dnb.com/us/. The D&B number
should be entered on line 11 of the face page of the PHS 398 form.
The title and number of this funding opportunity must be typed on line 2 of the
face page of the application form and the YES box must be checked.
Abstract (Overall Application Summary and Relevance)
It is especially important that the abstract (Description, PHS 398 form page 2) of your grant application reflects the overall application s (both core and research) focus, because if your application is funded, your abstract will become public information.
The language of the abstract must be simple and easy to understand for a broad audience.
For more information on how to write an abstract please see the Structured Abstracts section at: http://jama.ama-assn.org/ifora_current.dtl
Center Description
Applications should include the following information, detailing activities to be conducted for the first budget year, while briefly addressing activities to be conducted over the entire five-year project period.
Detailed budget
for the initial budget period: The budget should reflect the composite figures
for the grant. In addition, separate budgets (direct and indirect costs) and
justifications should be provided for the following categories of activities:
a. Core
activities, including management and administrative functions, other
non-research activities (e.g., education/training, consultation, technical
assistance, translation/dissemination, program and policy development and
evaluation, advocacy, and media activities, etc.), and small seed projects of
less than $25,000 (total of direct and indirect costs) for one year or less.
b. Research Studies:
(1) Small
studies of $25,000-150,000/year (total of direct and indirect costs) for one to
three years duration. These projects might be expansions of seed projects,
either further developing methods or hypotheses in preparation for a larger
investigation leading to the submission of an RO1 level (investigator-initiated)
proposal, or might be stand-alone investigations sufficient to yield results
worthy of publication in a peer-reviewed journal and/or a technical report for
a legislative body, governmental agency, or injury control program.
(2) Larger scale studies with annual budgets exceeding $150,000/year (total of direct and indirect costs) and lasting up to five years. These projects typically will test hypotheses and employ more sophisticated methodologies and/or larger sample sizes than small studies.
For seed projects, only modest budget descriptions are required within the application. More detailed budget descriptions, commensurate with costs, are required for both small studies and large research projects.
An applicant organization has the option of having specific salary and fringe benefit amounts for individuals omitted from the copies of the application which are made available to outside reviewing groups. To exercise this option: on the original and five copies of the application, the applicant must use asterisks to indicate those individuals for whom salaries and fringe benefits are not shown; however, the subtotals must still be shown. In addition, the applicant must submit an additional copy of page four of Form PHS-398, completed in full, with the asterisks replaced by the salaries and fringe benefits. This budget page will be reserved for internal staff use only.
The application should include:
Research Plan
(1) Initial seed projects require a short write-up describing the injury control context of the study, the objective, the design, the setting and participants, the intervention being addressed, main outcome measurements, expected results, time lines, cost (total of direct and indirect costs), plans for translation/dissemination, and clear definition of procedures used to select the projects. Clear definitions of procedures used to select future out-year seed projects are also required.
(2) Small research projects require a ten to fifteen page summary describing the accomplishment of all the steps, including a description of the significance of the project, the development and testing of methods and instruments, and the collection of preliminary data needed to take an innovative approach and develop it to the level of a larger investigation leading to the submission of an RO1 level proposal or a stand-alone investigation sufficient to yield results worthy of publication in a peer-reviewed journal and/or a technical report for a legislative body, governmental agency, or injury control program.
(3) Large research projects require an RO1 level summary (investigator-initiated proposal) as described in the PHS 398 (Revised 5/01 and updated 6/28/02) guidelines. The summary should be included as an appendix of the application.
In the research plan section of the application, include the following for each small and large research project:
(a.) Title of Project
(b.) Project Director/Lead Investigator
(c.) Institution(s)
(d.) Categorization as Prevention, Acute Care, Rehabilitation, or Biomechanics
(e.) Categorization as to which NCIPC research agenda priority area the project addresses. Also, a brief description on how it addresses that priority area. If a priority area is not addressed, provide an explanation of why it is important.
(f.) Categorization as Seed Project, Small Project, or Large Project
(g.) Categorization as New or Ongoing Project
(h.) Total Cost/Year (total of direct and indirect costs)
(i.) Research Training: Names, Degrees of Persons Trained or in Training
(j.) Key Words
(k.) Brief Summary (Abstract) of Project including Intended Application of Findings
3. Submission Dates and Times
All requested information
must be received in the CDC Procurement and Grants Office by 4:00 p.m. Eastern
Time on the deadline date. If you submit your application by the United States
Postal Service or commercial delivery service, you must ensure that the carrier
will be able to guarantee delivery by the closing date and time. If CDC
receives your submission after closing due to: (1) carrier error, when the
carrier accepted the package with a guarantee for delivery by the closing date
and time, or (2) significant weather delays or natural disasters, you will be
given the opportunity to submit documentation of the carrier’s guarantee. If
the documentation verifies a carrier problem, CDC will consider the submission
as having been received by the deadline.
This announcement is the definitive guide on LOI and application content, submission address, and deadline. It supersedes information provided in the application instructions. If your application does not meet the deadline above, it will not be eligible for review, and will be discarded. You will be notified that you did not meet the submission requirements.
Otherwise,
CDC will not notify you upon receipt of your submission. If you have a
question about the receipt of your LOI or application, first contact your
courier. If you still have a question, contact the PGO-TIM staff at:
770-488-2700. Before calling, please wait two to three days after the
submission deadline. This will allow time for submissions to be processed and
logged.
3.A.
Receipt, Review and Anticipated Start Dates
Letter of Intent Receipt
Date: 08/02/2006
Application
Receipt Date: 09/01/2006
Peer
Review Date: 03/10/2007
Council
Review Date: 04/12/2007
Earliest Anticipated Start Date: 09/01/2007
3.A.1. Letter of Intent
Prospective applicants are asked to submit a letter of intent
that includes the following information:
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows NCIPC staff to estimate the potential review workload and plan the review.
The letter of intent is to be sent by the date listed in Section IV.3.A
The letter
of intent should be sent to:
NCIPC Extramural Resources Team
CDC, National Center for Injury Prevention and Control
Address for Express Mail or Delivery Service:
2945 Flowers Road
Yale Building,
Room 2054
Atlanta, Georgia 30341
Address for U.S. Postal Service Mail:
4770 Buford Hwy, NE,
Mailstop K-62
Atlanta, GA 30341
Telephone: 770-488-4037
Fax: 770-488-1662
Email: [email protected]
3.B.
Sending an Application
Applications
follow the PHS 398 application instructions for content and formatting of your
applications. If the instructions in this announcement differ in any way from
the PHS 398 instructions, follow the instructions in this announcement.
Applications
must be prepared using the research grant applications found in the PHS 398
instructions for preparing a research grant application. Submit a signed, typewritten
original of the application and all appendices, including the checklist, and one
signed photocopy in one package to:
Technical Information Management PA CE07-001
CDC
Procurements and Grants Office
2920
Brandywine Road
Atlanta, GA 30341
At the time of submission, four additional copies of the application, including the appendix material, must be sent to:
NCIPC Extramural Resources Team
CDC, National Center for Injury Prevention and Control
Address for Express Mail or Delivery Service:
2945 Flowers Road
Yale Building,
Room 2054
Atlanta, Georgia 30341
Address for U.S. Postal Service Mail:
4770 Buford Hwy, NE,
Mailstop K-62
Atlanta, GA 30341
Fax: 770-488-1662
Email: [email protected]
Note: Applications must be sent to CDC in Atlanta, GA not NIH in Bethesda, MD.
3.C.
Application Processing
Applications must be received on or before the application receipt date(s) described
above (Section IV.3.A.). If an application is received after that date, it will be
returned to the applicant without review. Upon receipt, applications will be
evaluated for completeness by the PGO and responsiveness by the NCIPC. Incomplete
and non-responsive applications will not be reviewed.
4. Intergovernmental Review
Executive
Order 12372 does not apply to this program.
5. Funding
Restrictions
All CDC awards are subject to
the terms and conditions, cost principles, and other considerations described
in the PHS Grants
Policy Statement.
Restrictions, which must be taken into account while writing your budget, are as follows:
6. Other Submission Requirements
If
you are requesting indirect costs in your budget, you must include a copy of
your indirect cost rate agreement. If
your indirect cost rate is a provisional rate, the agreement should be less
than 12 months of age.
Your research plan should address activities to be conducted over the entire project period.
Plan for Sharing Research Data
The precise content of the data-sharing plan will vary, depending on the data being collected and how the investigator is planning to share the data. Applicants may wish to describe briefly the expected schedule for data sharing, the format of the final dataset, the documentation to be provided, whether or not any analytic tools also will be provided, whether or not a data-sharing agreement will be required and, if so, a brief description of such an agreement (including the criteria for deciding who can receive the data and whether or not any conditions will be placed on their use), and the mode of data sharing (e.g., under their own auspices by mailing a disk or posting data on their institutional or personal website, through a data archive or enclave). References to data sharing may also be appropriate in other sections of the application.
Note: Only proposals submitted to NCIPC for individual research projects of $500,000 or more in total (direct and indirect) costs per year require the applicant to include a data-sharing plan.
All applicants must include a plan for sharing research data in their application. The data sharing policy is available at http://www.cdc.gov/od/pgo/funding/ARs.htm under Additional Requirements 25 Release and Sharing of Data. All investigators responding to this funding opportunity should include a description of how final research data will be shared, or explain why data sharing is not possible.
The reasonableness of the data sharing plan or the rationale for not sharing research data will be assessed by the reviewers. However, reviewers will not factor the proposed data sharing plan into the determination of scientific merit or the priority score.
Sharing Research Resources
Not applicable.
Section V. Application Review Information
1. Criteria
The following will be
considered in making funding decisions:
2. Review and Selection Process
Applications that are
complete and responsive to the PA will
be evaluated for scientific and technical merit by an appropriate peer review
group convened by NCIPC in accordance with the review criteria stated below.
As part of the initial merit review, all responsive applications will:
The goals of CDC-supported research are to advance the understanding of health promotion and prevention of disease, injury, and disability, and enhance preparedness. In the written comments, reviewers will be asked to evaluate the application in order to judge the likelihood that the proposed research will have a substantial impact on the pursuit of these goals.
Significance: Does
this study address an important problem? If the aims of the application are
achieved, how will scientific knowledge or clinical practice be advanced? What
will be the effect of these studies on the concepts, methods, technologies,
treatments, services, or preventative interventions that drive this field?
Approach: Are the
conceptual or clinical framework, design, methods, and analyses adequately
developed, well integrated, well reasoned, and appropriate to the aims of the
project? Does the applicant acknowledge potential problem areas and consider
alternative tactics? Does the project include
plans to measure progress toward achieving the stated objectives? Is there an
appropriate work plan included?
Innovation: Is the
project original and innovative? For example: Does the project challenge
existing paradigms or clinical practice; address an innovative hypothesis or
critical barrier to progress in the field? Does the project develop or employ
novel concepts, approaches, methodologies, tools, or technologies for this
area?
Investigators: Are
the investigators appropriately trained and well suited to carry out this work?
Is the work proposed appropriate to the experience level of the principal
investigator and other researchers? Does the investigative team bring
complementary and integrated expertise to the project (if applicable)? Is there a prior history by the principal
investigator of conducting injury prevention or control research?
Environment: Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed studies benefit from unique features of the scientific environment, or subject populations, or employ useful collaborative arrangements? Is there evidence of institutional support? Is there an appropriate degree of commitment and cooperation of other interested parties as evidenced by letters of support detailing the nature and extent of the involvement?
Application Review
Competing supplemental grant awards may be made, when funds are available, to support research work or activities not previously approved by the IRG. Applications should be clearly labeled to denote their status as requesting supplemental funding support. These applications will be reviewed by the IRG and the secondary review group.
Awards will be made based on priority scores assigned to applications by the IRG, programmatic priorities and needs determined by a secondary review committee (the Advisory Committee for Injury Prevention and Control), and the availability of funds.
The IRG may recommend the application for a site visit review. For those applications recommended for a site visit review, a team of peer reviewers, including members of the IRG, will conduct on-site visits at each applicant institution, generate summary statements for the visits, and report the assessment to the IRG. Factors to be considered by the IRG include:
a. Seed projects will be evaluated collectively on the mechanism for solicitation of projects and on their technical/scientific merit review. Evaluation criteria have equal value.
b. Small projects will be evaluated individually on the significance of the project, the innovative approach, and the proposed methods for achieving an investigation sufficient to support a submission of an RO1 level (investigator-initiated) proposal and/or worthy of publication in a peer-reviewed journal and/or a technical report for a legislative body, governmental agency, or injury control program.c. Large projects will be evaluated individually according to existing RO1 level (investigator-initiated) project standards as described in the PHS 398 (Revised 5/01 and updated 6/28/02) guidelines. The application must have a minimum of one large research project approved in order to be recommended for further consideration
d. At least 80 percent of the costs (total direct and indirect costs) of the approved small and large research projects must be in alignment with the CDC Injury Research Agenda, http://www.cdc.gov/ncipc in order to be recommended for further consideration.
2.A. Additional Review
Criteria:
In addition to the above
criteria, the following items will continue to be considered in the
determination of scientific merit and the priority score:
Protection
of Human Subjects from Research Risk: The involvement of human subjects and protections
from research risk relating to their participation in the proposed research
will be assessed (see the Research Plan, Section E on Human Subjects in the PHS
Form 398). http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm.
Additional CDC Requirements under AR-1 Human Subjects Requirements can be
found on http://www.cdc.gov/od/pgo/funding/ARs.htm.
Inclusion of Women and Minorities in Research: Does the application adequately address the CDC Policy requirements regarding the inclusion of women, ethnic, and racial groups in the proposed research? This includes: (1) The proposed plan for the inclusion of both sexes and racial and ethnic minority populations for appropriate representation; (2) The proposed justification when representation is limited or absent; (3) A statement as to whether the design of the study is adequate to measure differences when warranted; and (4) A statement as to whether the plans for recruitment and outreach for study participants include the process of establishing partnerships with community(ies) and recognition of mutual benefits.
Care
and Use of Vertebrate Animals in Research: If vertebrate animals are to be used
in the project, the five items described under Section F of the PHS Form 398
research grant application instructions will be assessed.
Additional CDC
Requirements under AR-3 Animal Subjects Requirements can be found on http://www.cdc.gov/od/pgo/funding/ARs.htm.
Biohazards: If materials or procedures are proposed that are potentially hazardous to
research personnel and/or the environment, determine if the proposed protection
is adequate.
2.B. Additional Review
Considerations
Budget: The reasonableness of the proposed
budget and the requested period of support in relation to the proposed
research. The priority score should not be affected by the evaluation of the
budget.
2.C. Sharing Research Data
Data Sharing Plan: The reasonableness of the data sharing plan or the rationale for not sharing research data will be assessed by the reviewers. However, reviewers will not factor the proposed data sharing plan into the determination of scientific merit or the priority score. The presence of a data sharing plan will be part of the terms and conditions of the award. The funding organization will be responsible for monitoring the data sharing policy.
Note: A data sharing plan is required by NCIPC only for applications requesting total (direct and indirect) costs of $500,000 or more per year.
2.D. Sharing Research Resources
Not applicable.
3. Anticipated Announcement and Award Dates
Applicants will be notified in August or early September of 2007 by
CDC’s Procurement and Grants Office (PGO) if their applications were funded.
Section VI. Award
Administration Information
1. Award Notices
After the peer review of the
application is completed, the Principal Investigator will also receive a written
critique called a Summary Statement.
Those
applicants under consideration for funding will be contacted by CDC for
additional information.
A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization. The notice of award signed by the Grants Management Officer (GMO) is the authorizing document. This document will be mailed and/or emailed to the recipient fiscal officer identified in the application.
Selection
of the application for award is not an authorization to begin performance. Any
cost incurred before receipt of the NoA is at the recipient’s risk. These
costs may be reimbursed only to the extent considered allowable pre-award
costs. See also Section IV.5. Funding Restrictions.
2. Administrative and National
Policy Requirements
The Code of Federal
Regulations 45 CFR Part 74 and Part 92 have details about policy requirements.
For more information on the Code of Federal Regulations, see the National
Archives and Records Administration at the following Internet address: http://www.access.gpo.gov/nara/cfr/cfr-table-search.html.
The following additional requirements can be found in Section VIII. Other
Information of this document or on the CDC website at the following Internet
address: http://www.cdc.gov/od/pgo/funding/ARs.htm.
These will be incorporated into the NoA by reference.
3. Reporting
You must provide CDC with an
original, plus two hard copies of the following reports:
Although the financial plans of the CIO(s) provide support for this program, awards pursuant to this funding opportunity are contingent upon the availability of funds, evidence of satisfactory progress by the recipient (as documented in required reports) and the determination that continued funding is in the best interest of the Federal government.
We
encourage your inquiries concerning this funding opportunity and welcome the
opportunity to answer questions from potential applicants. Inquiries may fall
into three areas: scientific/research, peer review, and financial or grants
management issues:
1. Scientific/Research Contacts:
Rick Waxweiler, Ph.D.
National Center for
Injury Prevention and Control
Centers for Disease Control and Prevention (CDC)
4770 Buford Highway, NE, Mailstop K-02
Atlanta, Georgia 30341
Telephone: 770-488-4823
FAX: 770-488-4422
E-mail: [email protected]
2. Peer Review Contacts:
Gwendolyn
Cattledge, Ph.D
Scientific Review
Administrator
National Center for Injury Prevention and Control
Centers for Disease
Control and Prevention (CDC)
4770 Buford Highway, NE, Mailstop K-02
Atlanta, Georgia 30341
Telephone:
770-488-4655
FAX: 770-488-4422
E-mail:
[email protected]
3. Financial or Grants Management Contacts:
Jim Masone, Grants Management Officer
CDC Procurement and Grants Office
2920 Brandywine Road
Atlanta, GA 30341
Telephone: 770-488-2736
FAX: 770-488-2671
E-mail: [email protected]
4. General Questions Contacts:
Technical Information
Management Section
CDC
Procurement and Grants Office
2920
Brandywine Road
Atlanta, GA 30341
Telephone:
770-488-2700
Email: [email protected]
Section VIII. Other Information
Required Federal Citations
Human Subjects Protection:
Federal regulations (45CFR46) require that applications and
proposals involving human subjects must be evaluated with reference to the
risks to the subjects, the adequacy of protection against these risks, the
potential benefits of the research to the subjects and others, and the
importance of the knowledge gained or to be gained (http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm).
Additional CDC Requirements under AR-1 Human Subjects Requirements can be found
on http://www.cdc.gov/od/pgo/funding/ARs.htm.
Use of Animals in Research:
Recipients of PHS support for activated involving live,
vertebrate animals must comply with PHS Policy on Humane Care and Use of
Laboratory Animals(http://grants.nih.gov/grants/olaw/references/PHSPolicyLabAnimals.pdf)
as mandated by the Health Research Extension Act of 1985 (http://grants.nih.gov/grants/olaw/references/hrea1985.htm),
and the USDA Animal Welfare Regulations (http://www.nal.usda.gov/awic/legislat/usdaleg1.htm)
as applicable. Additional CDC Requirements under AR-3 Animal Subjects
Requirements can be found on http://www.cdc.gov/od/pgo/funding/ARs.htm.
Requirements for Inclusion of Women and Racial and
Ethnic Minorities in Research
It is the policy of the Centers for
Disease Control and Prevention (CDC) and the Agency for Toxic Substances and
Disease Registry (ATSDR) to ensure that individuals of both sexes and the
various racial and ethnic groups will be included in CDC/ATSDR-supported
research projects involving human subjects, whenever feasible and appropriate.
Racial and ethnic groups are those defined in OMB Directive No. 15 and include
American Indian or Alaska Native, Asian, Black or African American, Hispanic or
Latino, Native Hawaiian or Other Pacific Islander. Applicants shall ensure that
women, racial and ethnic minority populations are appropriately represented in
applications for research involving human subjects. Where clear and compelling
rationale exist that inclusion is inappropriate or not feasible, this situation
must be explained as part of the application. This policy does not apply to
research studies when the investigator cannot control the race, ethnicity,
and/or sex of subjects. Further guidance to this policy is contained in the
Federal Register, Vol. 60, No. 179, pages 47947-47951, and dated Friday,
September 15, 1995.
Paperwork
Reduction Act Requirements
Under the
Paperwork Reduction Act, projects that involve the collection of information
from 10 or more individuals and funded by a grant or a cooperative agreement
will be subject to review and approval by the Office of Management and Budget
(OMB).
Smoke-Free
Workplace Requirements
CDC strongly
encourages all recipients to provide a smoke-free workplace and to promote
abstinence from all tobacco products. Public Law 103-227, the Pro-Children Act
of 1994, prohibits smoking in certain facilities that receive Federal funds in
which education, library, day care, health care, or early childhood development
services are provided to children.
Healthy People 2010
The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2010," a PHS-led national activity for setting priority areas. This PA is related to one or more of the priority areas. Potential applicants may obtain a copy of "Healthy People 2010" at http://www.health.gov/healthypeople.
Lobbying RestrictionsApplicants should be aware of restrictions on the use of HHS funds for lobbying of Federal or State legislative bodies. Under the provisions of 31 U.S.C. Section 1352, recipients (and their sub-tier contractors) are prohibited from using appropriated Federal funds (other than profits from a Federal contract) for lobbying congress or any Federal agency in connection with the award of a particular contract, grant, cooperative agreement, or loan. This includes grants/cooperative agreements that, in whole or in part, involve conferences for which Federal funds cannot be used directly or indirectly to encourage participants to lobby or to instruct participants on how to lobby.
In addition no part of CDC appropriated funds, shall be used, other than for normal and recognized executive-legislative relationships, for publicity or propaganda purposes, for the preparation, distribution, or use of any kit, pamphlet, booklet, publication, radio, television, or video presentation designed to support or defeat legislation pending before the Congress or any State or local legislature, except in presentation to the Congress or any State or local legislature itself. No part of the appropriated funds shall be used to pay the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence legislation or appropriations pending before the Congress or any State or local legislature.
Any activity designed to influence action in regard to a particular piece of pending legislation would be considered "lobbying." That is lobbying for or against pending legislation, as well as indirect or "grass roots" lobbying efforts by award recipients that are directed at inducing members of the public to contact their elected representatives at the Federal or State levels to urge support of, or opposition to, pending legislative proposals is prohibited. As a matter of policy, CDC extends the prohibitions to lobbying with respect to local legislation and local legislative bodies.
The provisions are not intended to prohibit all interaction with the legislative branch, or to prohibit educational efforts pertaining to public health. Clearly there are circumstances when it is advisable and permissible to provide information to the legislative branch in order to foster implementation of prevention strategies to promote public health. However, it would not be permissible to influence, directly or indirectly, a specific piece of pending legislation
It remains permissible to use CDC funds to engage in activity to enhance prevention; collect and analyze data; publish and disseminate results of research and surveillance data; implement prevention strategies; conduct community outreach services; provide leadership and training, and foster safe and healthful environments.
Recipients of CDC grants and cooperative agreements need to be careful to prevent CDC funds from being used to influence or promote pending legislation. With respect to conferences, public events, publications, and "grassroots" activities that relate to specific legislation, recipients of CDC funds should give close attention to isolating and separating the appropriate use of CDC funds from non-CDC funds. CDC also cautions recipients of CDC funds to be careful not to give the appearance that CDC funds are being used to carry out activities in a manner that is prohibited under Federal law.
Prohibition
on Use of CDC Funds for Certain Gun Control Activities
The Departments of
Labor, Health and Human Services, and Education, and Related Agencies Appropriations
Act specifies that: "None of the funds made available for injury
prevention and control at the Centers for Disease Control and Prevention may be
used to advocate or promote gun control."
Anti-Lobbying Act requirements prohibit lobbying Congress with appropriated Federal monies. Specifically, this Act prohibits the use of Federal funds for direct or indirect communications intended or designed to influence a member of Congress with regard to specific Federal legislation. This prohibition includes the funding and assistance of public grassroots campaigns intended or designed to influence members of Congress with regard to specific legislation or appropriation by Congress.
In addition to the restrictions in the Anti-Lobbying Act, CDC interprets the language in the CDC's Appropriations Act to mean that CDC's funds may not be spent on political action or other activities designed to affect the passage of specific Federal, State, or local legislation intended to restrict or control the purchase or use of firearms.
Small, Minority, And Women-owned Business
It is a national
policy to place a fair share of purchases with small, minority and women-owned
business firms. The Department of Health and Human Services is strongly
committed to the objective of this policy and encourages all recipients of its
grants and cooperative agreements to take affirmative steps to ensure such
fairness. In particular, recipients should:
Proof of Non-profit Status
Proof of nonprofit status must be submitted by private
nonprofit organizations with the application. Any of the following is
acceptable evidence of nonprofit status: (a) a reference to the applicant
organization's listing in the Internal Revenue Service's (IRS) most recent list
of tax-exempt organizations described in section 501(c)(3) of the IRS Code; (b)
a copy of a currently valid IRS tax exemption certificate; (c) a statement from
a State taxing body, State Attorney General, or other appropriate State
Official certifying that the applicant organization has a nonprofit status and
that none of the net earnings accrue to any private shareholders or
individuals; (d) a certified copy of the organization's certificate of
incorporation or similar document that clearly establishes nonprofit status;
(e) any of the above proof for a State or national parent organization and a
statement signed by the parent organization that the applicant organization is
a local nonprofit affiliate.
Research Integrity
The
signature of the institution official on the face page of the application
submitted under this Program Announcement is certifying compliance with the
Department of Health and Human Services (DHHS) regulations in 42 CFR Part 93 entitled
"Responsibility of PHS Awardee and Applicant Institutions for Dealing with
and Reporting Possible Misconduct in Science."
The regulation places several requirements on institutions receiving or applying for funds under the PHS Act that are monitored by the DHHS Office of Research Integrity's (ORI) Assurance Program.
For examples:
Section 50.103(a) of the regulation states: "Each institution that applies for or receives assistance under the Act for any project or program which involves the conduct of biomedical or behavioral research must have an assurance satisfactory to the Secretary (DHHS) that the applicant: (1) Has established an administrative process, that meets the requirements of this subpart, for reviewing, investigating, and reporting allegations of misconduct in science in connection with PHS-sponsored biomedical and behavioral research conducted at the applicant institution or sponsored by the applicant; and (2) Will comply with its own administrative process and the requirements of this Subpart."
Section 50.103(b) of the regulation states that: "an applicant or recipient institution shall make an annual submission to the [ORI] as follows: (1) The institution's assurance shall be submitted to the [ORI], on a form prescribed by the Secretary,...and updated annually thereafter...(2) An institution shall submit, along with its annual assurance, such aggregate information on allegations, inquiries, and investigations as the Secretary may prescribe."
An additional policy is added in the year 2000 that "requires research institutions to provide training in the responsible conduct of research to all staff engaged in research or research training with PHS funds.
Health Insurance
Portability and Accountability Act Requirements
Recipients of this
grant award should note that pursuant to the Standards for Privacy of
Individually Identifiable Health Information promulgated under the Health
Insurance Portability and Accountability Act (HIPAA) (45 CFR Parts 160 and 164)
covered entities may disclose protected health information to public health
authorities authorized by law to collect or receive such information for the
purpose of preventing or controlling disease, injury, or disability, including,
but not limited to, the reporting of disease, injury, vital events such as
birth or death, and the conduct of public health surveillance, public health
investigations, and public health interventions. The definition of a public
health authority includes a person or entity acting under a grant of authority
from or contract with such public agency. CDC considers this project a public
health activity consistent with the Standards for Privacy of Individually
Identifiable Health Information and CDC will provide successful recipients a
specific grant of public health authority for the purposes of this project.
Release and
Sharing of Data
The Data Release
Plan is the Grantee's assurance that the dissemination of any and all data
collected under the CDC data sharing agreement will be released as follows:
a. In a timely manner.
b. Completely, and as accurately as possible.
c. To facilitate the broader community.
d. Developed in accordance with CDC policy on Releasing and Sharing Data.
April 16, 2003, http://www.cdc.gov/od/foia/policies/sharing.htm and in full compliance with the 1996 Health Insurance Portability and Accountability Act (HIPPA), (where applicable), The Office of Management and Budget Circular A110, (2000) revised 2003, www.whitehouse.gov/omb/query.html?col=omb&qt=Releasing+and+Sharing+of+Data and Freedom of Information Act (FOIA) www.4.law.cornell.edu/uscode/5/5/552/html
Applications must include a copy of the applicant's Data Release Plan. Applicants should provide CDC with appropriate documentation on the reliability of the data. Applications submitted without the required Plan may be ineligible for award. Award will be made when reviewing officials have approved an acceptable Plan. The successful applicant and the Program Manager will determine the documentation format. CDC recommends data is released in the form closest to micro data and one that will preserve confidentiality.
Note: Only proposals submitted to NCIPC for individual research projects of $500,000 or more in total (direct and indirect) costs per year require the applicant to include a data-sharing plan.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
| ||||||
|
|
|
Department of Health and Human Services (HHS) |
|
|||
|
NIH... Turning Discovery Into Health® |
||||||